Idenix Pharmaceuticals News

Idenix Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference

CAMBRIDGE, Mass. -- Idenix Pharmaceuticals, Inc. announced today that Idenix management will present a corporate overview at the Wells Fargo Securities 2013 Healthcare Conference on Tuesday, June 18, 2013, ...

IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex

Idenix Pharmaceuticals Appoints Charles Rowland to Its Board of Directors

CAMBRIDGE, Mass. -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has appointed ...

Idenix Pharmaceuticals Announces Samatasvir (IDX719) Poster Presentations at the Asian Pacific Association for the Study of the Liver (APASL) Conference

CAMBRIDGE, Mass. -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced three poster ...

Why Idenix Is Poised to Pull Back

Market-lagging returns could be written in this 2-Star.

Idenix Pharma Initiates Phase II Study

Commit To Buy Idenix Pharmaceuticals At $3, Earn 20%

Investors considering a purchase of Idenix Pharmaceuticals Inc stock, but cautious about paying the going market price of $4.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $3 strike, which has a bid at the time of this writing of 60 cents.

Idenix Pharmaceuticals' CEO Presents at Deutsche Bank Securities 38th Annual Health Care Conference (Transcript)

Idenix Pharmaceuticals' CEO Presents at Deutsche Bank Securities 38th Annual Health Care Conference (Transcript)

4 Healthcare Stock Stories Prescribed For Savvy Investors

Idenix Pharma (IDIX) Initiates Phase II HELIX-1

Idenix Pharmaceuticals Announces Initiation of Phase II All-Oral Combination Study of Samatasvir (IDX719) and Simeprevir (TMC435) for the Treatment of Hepatitis C Virus (HCV) Infection

CAMBRIDGE, Mass. -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the initiation ...

Idenix Pharmaceuticals' CEO Presents at UBS Global Healthcare Services Conference (Transcript)

Idenix Pharmaceuticals' CEO Presents at UBS Global Healthcare Services Conference (Transcript)

Idenix Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)

Idenix Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)

Seth Klarman's Worst Performing Stock Picks Year-To-Date

Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences

CAMBRIDGE, Mass. -- Idenix Pharmaceuticals, Inc. , announced today that Idenix management will present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, ...